NAD+

Description

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is arguably the most important coenzyme in human biology. It participates in over 500 enzymatic reactions and is essential for cellular energy metabolism, DNA repair, gene expression regulation, calcium signaling, and immune function. NAD+ is not a peptide — it is a dinucleotide composed of two nucleotides (nicotinamide mononucleotide and adenosine monophosphate) joined by a phosphodiester bond. Despite not being a peptide, it is included in the research peptide market due to its injectable formulation and its central role in the longevity research space.

NAD+ functions as an electron carrier in metabolic redox reactions, shuttling electrons between enzymes in glycolysis, the citric acid cycle, and oxidative phosphorylation (the mitochondrial electron transport chain). Without adequate NAD+, cells cannot efficiently convert nutrients into ATP (cellular energy). But beyond its metabolic role, NAD+ has become one of the most intensively studied molecules in aging research because of its role as a co-substrate (not just a cofactor — it is consumed, not recycled) for three critical families of enzymes:

1. Sirtuins (SIRT1-7): A family of NAD+-dependent deacetylases and ADP-ribosyltransferases that regulate aging-related processes including DNA repair, inflammatory response, mitochondrial biogenesis, circadian rhythm, and metabolic adaptation. Sirtuins require NAD+ as a co-substrate — when NAD+ levels decline with age, sirtuin activity decreases proportionally, contributing to age-related cellular dysfunction. SIRT1 activation (the "longevity gene" pathway originally linked to caloric restriction benefits) is directly dependent on NAD+ availability.

2. PARPs (Poly-ADP-Ribose Polymerases): Enzymes that consume NAD+ to facilitate DNA repair. PARP1 is the primary DNA damage sensor and repair enzyme in cells. As DNA damage accumulates with age (from oxidative stress, UV, environmental toxins), PARP activity increases, consuming more NAD+ and depleting the pool available for sirtuins — creating a vicious cycle where DNA damage leads to NAD+ depletion which leads to reduced sirtuin activity which leads to further cellular decline.

3. CD38: An ectoenzyme that degrades NAD+ and whose expression increases with age and chronic inflammation. CD38 is now recognized as the primary driver of age-related NAD+ decline — its activity increases 2-3x between young and old tissue, directly consuming the available NAD+ pool.

The age-related decline in NAD+ levels is one of the most well-documented biochemical changes associated with aging. NAD+ levels drop approximately 50% between ages 40 and 60 in human tissues. This decline correlates with (and may directly contribute to) mitochondrial dysfunction, impaired DNA repair capacity, epigenetic drift, stem cell exhaustion, chronic inflammation (inflammaging), and metabolic dysfunction — all hallmarks of the aging process. Restoring NAD+ levels to youthful concentrations has been shown in animal models to reverse many of these aging phenotypes, including improving mitochondrial function, enhancing stem cell regeneration, improving cognitive function, extending lifespan (in mice and worms), and restoring metabolic flexibility.

Clinical Context

NAD+ IV infusion clinics have proliferated in major cities worldwide, offering 250mg-1000mg IV NAD+ drips for anti-aging, energy, addiction recovery, and cognitive enhancement. These clinics typically charge $500-$1,500 per infusion session. The injectable form (subcutaneous or IM) offers a more accessible and affordable delivery method than IV infusion.

The Standard Catalog YPB.101 (Biofermented, 5ml Vial) represents a different formulation — a pre-dissolved liquid form produced by biofermentation rather than chemical synthesis, potentially offering different bioavailability characteristics.

Oral NAD+ precursors (NMN — nicotinamide mononucleotide, and NR — nicotinamide riboside) are widely available as dietary supplements but have lower bioavailability than injectable NAD+ due to first-pass hepatic metabolism and limited intestinal absorption.